+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bleeding Disorder Diagnostics Market - Global Forecast to 2030- Product Image
Bleeding Disorder Diagnostics Market - Global Forecast to 2030- Product Image
Sale

Bleeding Disorder Diagnostics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5968399
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bleeding Disorder Diagnostics Market grew from USD 710.26 million in 2024 to USD 765.34 million in 2025. It is expected to continue growing at a CAGR of 7.69%, reaching USD 1.10 billion by 2030.

Bleeding disorders represent a complex and multifaceted segment of hematology, where accurate and timely diagnostic practices form the cornerstone of effective patient management. Advances in molecular biology, imaging technologies, and hospital-based laboratory protocols have converged to reshape how clinicians identify and monitor conditions such as hemophilia, von Willebrand disease and rare factor deficiencies. Today’s diagnostic ecosystem demands integration of traditional coagulation assays with cutting-edge genetic and imaging modalities to deliver personalized care pathways.

As global awareness of bleeding disorders rises, regulatory bodies, clinical networks and payers seek robust data on diagnostic performance, cost efficiency and patient outcomes. This summary outlines key dynamics affecting the bleeding disorder diagnostics landscape, including regulatory shifts, tariff implications, segmentation strategies, regional nuances and leading industry players. By synthesizing these insights, stakeholders can navigate complexity, mitigate risk and seize opportunities for innovation and collaboration.

In the sections that follow, readers will explore transformative shifts driven by technology, the cumulative impact of upcoming tariff adjustments in the United States, precise segmentation insights spanning disorder types, test modalities and end users, as well as regional and corporate benchmarks. Ultimately, this executive summary equips decision-makers with actionable recommendations aimed at bolstering diagnostic accuracy, streamlining supply chains and enhancing patient access across diverse markets.

Transformative Shifts Redefining Diagnostic Approaches

Over the past decade, bleeding disorder diagnostics has undergone a fundamental realignment driven by three core trends. First, the decentralization of testing from centralized labs to point-of-care and near-patient platforms has accelerated adoption of rapid coagulation and platelet function assays in clinics and emergency settings. Second, the integration of next-generation sequencing and mutation analysis into routine workflows has enabled precise characterization of genetic variants in hemophilia A, hemophilia B and von Willebrand disease, supporting personalized treatment protocols. Third, advanced imaging modalities such as MRI-based joint assessments and high-resolution CT have enhanced the evaluation of hemorrhagic complications, guiding treatment planning and long-term monitoring.

Moreover, collaborative networks between diagnostic laboratories, research institutes and biopharma companies increasingly emphasize data sharing and harmonized standards, fostering open innovation. As a result, regulatory agencies are updating guidelines to accommodate novel diagnostic agents while maintaining stringent quality and safety requirements. In parallel, digital health platforms and artificial intelligence tools are emerging to automate result interpretation, flag aberrations and predict bleeding risk profiles. Collectively, these transformative shifts are redefining the bleeding disorder diagnostics landscape and laying the groundwork for more efficient, accurate, and patient-centric care.

Cumulative Impact of 2025 United States Tariffs

On January 1, 2025, the United States implemented revised tariff schedules targeting a range of diagnostic reagents, instruments and ancillary supplies. This policy change has exerted a notable impact on cost structures across the diagnostic value chain. Import duties on specialized reagents used in coagulation assays, genetic testing kits and imaging contrast agents have increased by up to 10 percent, compelling diagnostic laboratories and hospitals to reassess sourcing strategies. Simultaneously, equipment manufacturers faced higher levies on high-end analyzers and imaging scanners, prompting a shift toward domestic production or alternative supply agreements.

Consequently, many end users have begun negotiating long-term contracts with local distributors to secure stable pricing and reduce exposure to volatility. Meanwhile, research institutes are exploring in-house reagent development to mitigate dependency on imported materials. As laboratories adapt to these constraints, they emphasize process optimization, inventory management and collaborative purchasing to preserve diagnostic throughput and patient service levels. Looking ahead, stakeholders must remain vigilant to further regulatory adjustments, align procurement practices with evolving tariff regimes and strengthen supply chain resilience to safeguard continuity of care.

Key Segmentation Insights Across Diagnostic Dimensions

Diagnostic strategies for bleeding disorders hinge on nuanced segmentation across disorder categories, test modalities and end-user settings. Based on disorder type, analysis encompasses hemophilia, which itself subdivides into hemophilia A and hemophilia B; rare bleeding disorders including Factor I, II, V + VIII, V, VII, X, XI and XIII deficiencies; and von Willebrand disease covering Type 1, Type 2 and Type 3 variants. Shifting to diagnostic modality, blood tests-encompassing both coagulation assays and platelet function analyses-remain foundational, while genetic testing through DNA sequencing and targeted mutation analysis delivers definitive molecular diagnoses. Imaging tests, led by computed tomography and magnetic resonance imaging, provide critical insights into structural damage and hemorrhagic sequelae. Finally, end users span clinical practices, diagnostic laboratories, hospitals and research institutes, each presenting distinct throughput requirements, regulatory frameworks and reimbursement landscapes.

By aligning product portfolios and service offerings with these interlocking segments, manufacturers can tailor solutions that address the unique needs of each clinical pathway and end-user environment. This granular approach not only enhances diagnostic accuracy and workflow efficiency but also supports cost-effective deployment in diverse healthcare settings.

Key Regional Insights Shaping Market Dynamics

Regional dynamics play a pivotal role in shaping bleeding disorder diagnostics, driven by variations in healthcare infrastructure, regulatory oversight, reimbursement policies and disease prevalence. In the Americas, established laboratory networks and advanced hospital systems underpin high adoption of complex genetic and imaging tests, while payer mandates encourage comprehensive diagnostic panels. Contrastingly, the Europe, Middle East & Africa region exhibits heterogeneity: Western Europe leads with integrated digital reporting and point-of-care platforms, whereas emerging markets in Eastern Europe and the Middle East focus on scaling basic coagulation assays and building laboratory capacity. In Africa, limited resources prioritize rapid, low-cost point-of-care diagnostics to bridge access gaps. Meanwhile, Asia-Pacific demonstrates robust growth fueled by public-private partnerships, localized manufacturing of reagents and government initiatives to enhance rare disease registries. Countries such as Japan, South Korea and Australia deploy advanced MRI protocols for joint assessment, while Southeast Asia and India expand mobile clinics to reach rural populations.

Understanding these regional nuances enables suppliers to optimize distribution models, tailor value propositions and collaborate with local stakeholders to drive sustainable market growth and improve patient outcomes across diverse territories.

Key Companies Driving Diagnostic Innovation

Leading companies in bleeding disorder diagnostics are driving innovation through strategic R&D investments, collaborative partnerships and product diversification. Industry incumbents such as Abbott Laboratories and F. Hoffmann-La Roche Ltd. continue to refine high-throughput analyzers and next-generation sequencing platforms, while specialized diagnostics firms like Bio-Rad Laboratories, Inc. and Cepheid by Danaher Corporation focus on expanding molecular point-of-care assays. Global healthcare conglomerates including Bayer AG and Baxter International Inc. leverage broad distribution networks to integrate diagnostic reagents with therapeutics, enhancing treatment monitoring workflows. Additionally, entities such as ARUP Laboratories and Laboratory Corporation of America Holdings offer extensive reference testing services and genetic consultation, supporting comprehensive diagnostics.

Meanwhile, emerging players like rHEALTH and Precision BioLogic introduce portable devices and innovative assay formats, challenging traditional laboratory models. Technology companies such as HORIBA, Ltd. and Siemens AG bring expertise in imaging hardware and informatics, enabling advanced joint imaging and data analytics. Moreover, pharmaceutical companies like Novo Nordisk A/S and Takeda Pharmaceutical Company Limited collaborate with diagnostic developers to co-create companion diagnostics, aligning molecular tests with novel therapies. Finally, multinational life science tool providers including Thermo Fisher Scientific Inc. and CSL Limited support universal assay design and reagent manufacturing, ensuring consistent supply and quality. Together, these companies are shaping a competitive landscape that balances scale, specialization and technological breakthroughs.

Actionable Recommendations for Industry Leaders

Industry leaders must adopt a multifaceted approach to capitalize on evolving diagnostic paradigms and ensure sustained growth. First, invest in modular platforms that integrate coagulation assays, genetic testing and imaging data within unified software environments, enabling seamless workflows and remote collaboration. At the same time, strengthen partnerships with local distributors and manufacturers to offset tariff pressures and streamline supply chains. Additionally, adopt agile procurement models that leverage bulk purchasing and reagent reusability, reducing operational costs without compromising quality. Furthermore, prioritize validation studies and real-world evidence generation to demonstrate clinical utility, support regulatory submissions and secure favorable reimbursement.

In parallel, expand training programs for laboratory personnel and clinicians, facilitating adoption of novel assays and imaging protocols. Engage with patient advocacy groups and rare disease registries to gather epidemiological data and tailor diagnostic services to underserved populations. Leverage artificial intelligence and machine learning to automate result interpretation, predict bleeding risk and personalize testing schedules. Finally, embed sustainability practices across manufacturing and distribution, minimizing environmental impact while meeting global health objectives. By executing these strategic recommendations, stakeholders can enhance diagnostic accuracy, optimize resource utilization and ultimately improve patient outcomes in bleeding disorders.

Conclusion: Synthesizing Critical Findings

This executive summary has distilled critical insights into the bleeding disorder diagnostics market, highlighting transformative technological shifts, tariff-induced supply chain recalibrations and detailed segmentation across disorder types, test modalities and end-user environments. Regional variations underscore the need for customized strategies, while a diverse array of industry players-from established conglomerates to nimble innovators-drives competitive momentum. The actionable recommendations presented herein offer a roadmap for aligning product development, partnership models and operational frameworks with the evolving needs of patients and providers.

By synthesizing these findings, decision-makers can navigate regulatory complexities, manage cost pressures and leverage emerging technologies to deliver precise, efficient and accessible diagnostics. This holistic perspective empowers stakeholders to seize growth opportunities while advancing the standard of care for individuals affected by bleeding disorders.

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Hemophilia
    • Hemophilia A
    • Hemophilia B
  • Rare Bleeding Disorders
    • Factor I Deficiency
    • Factor II Deficiency
    • Factor V + VIII Deficiency
    • Factor V Deficiency
    • Factor VII Deficiency
    • Factor X Deficiency
    • Factor XI Deficiency
    • Factor XIII Deficiency
  • Von Willebrand Disease
    • Type 1
    • Type 2
    • Type 3
  • Blood Test
    • Coagulation Tests
    • Platelet Function Tests
  • Genetic Testing
    • DNA Sequencing
    • Mutation Analysis
  • Imaging Tests
    • CT Scan
    • MRI Scan
  • Clinics
  • Diagnostic Laboratories
  • Hospitals
  • Research Institutes

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bleeding Disorder Diagnostics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • ARUP Laboratories
  • Baxter International Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Cepheid by Danaher Corporation
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • Hyphen BioMed by Sysmex Corporation
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Precision BioLogic
  • rHEALTH
  • Siemens AG
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bleeding Disorder Diagnostics Market, by Type of Bleeding Disorder
8.1. Introduction
8.2. Hemophilia
8.2.1. Hemophilia A
8.2.2. Hemophilia B
8.3. Rare Bleeding Disorders
8.3.1. Factor I Deficiency
8.3.2. Factor II Deficiency
8.3.3. Factor V + VIII Deficiency
8.3.4. Factor V Deficiency
8.3.5. Factor VII Deficiency
8.3.6. Factor X Deficiency
8.3.7. Factor XI Deficiency
8.3.8. Factor XIII Deficiency
8.4. Von Willebrand Disease
8.4.1. Type 1
8.4.2. Type 2
8.4.3. Type 3
9. Bleeding Disorder Diagnostics Market, by Type of Diagnostic Test
9.1. Introduction
9.2. Blood Test
9.2.1. Coagulation Tests
9.2.2. Platelet Function Tests
9.3. Genetic Testing
9.3.1. DNA Sequencing
9.3.2. Mutation Analysis
9.4. Imaging Tests
9.4.1. CT Scan
9.4.2. MRI Scan
10. Bleeding Disorder Diagnostics Market, by End-User
10.1. Introduction
10.2. Clinics
10.3. Diagnostic Laboratories
10.4. Hospitals
10.5. Research Institutes
11. Americas Bleeding Disorder Diagnostics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Bleeding Disorder Diagnostics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2024
14.2. FPNV Positioning Matrix, 2024
14.3. Competitive Analysis
14.3.1. Abbott Laboratories
14.3.2. ARUP Laboratories
14.3.3. Baxter International Inc.
14.3.4. Bayer AG
14.3.5. Bio-Rad Laboratories, Inc.
14.3.6. Cepheid by Danaher Corporation
14.3.7. CSL Limited
14.3.8. F. Hoffmann-La Roche Ltd.
14.3.9. HORIBA, Ltd.
14.3.10. Hyphen BioMed by Sysmex Corporation
14.3.11. Laboratory Corporation of America Holdings
14.3.12. Novo Nordisk A/S
14.3.13. Precision BioLogic
14.3.14. rHEALTH
14.3.15. Siemens AG
14.3.16. Takeda Pharmaceutical Company Limited
14.3.17. Thermo Fisher Scientific Inc.
15. ResearchAI
16. ResearchStatistics
17. ResearchContacts
18. ResearchArticles
19. Appendix
List of Figures
FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR I DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR II DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR V + VIII DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR V DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR VII DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR X DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR XI DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY FACTOR XIII DEFICIENCY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY MRI SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 73. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 74. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 75. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 76. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 77. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 78. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 79. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 80. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 82. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 83. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 84. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 88. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 120. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 121. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 122. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 123. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 124. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 125. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 126. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 127. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 129. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 130. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 131. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 132. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 133. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 134. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 135. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 136. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 145. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 147. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 148. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 149. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 150. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 151. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 152. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 153. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 154. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 163. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 189. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 190. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 198. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 199. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 201. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 202. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 203. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 204. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 205. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 206. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 207. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 208. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 216. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 217. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 231. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 232. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 233. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 234. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 235. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 236. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 238. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 239. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 240. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 242. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 243. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 244. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 247. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 248. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 249. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 250. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 251. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 252. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 253. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 254. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 256. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 257. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 258. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 259. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 260. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 261. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 262. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 263. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 265. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 266. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 268. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 269. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 270. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 271. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 272. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 281. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 283. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 284. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 286. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 287. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 288. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 289. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 290. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY RARE BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLOOD TEST, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 300. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY TYPE OF BLEEDING DISORDER, 2018-2030 (USD MILLION)
TABLE 301. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA, 2018-2030 (USD MILLION)
TABLE 302. NIGERIA BLEEDING DISORDER D

Companies Mentioned

  • Abbott Laboratories
  • ARUP Laboratories
  • Baxter International Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Cepheid by Danaher Corporation
  • CSL Limited
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • Hyphen BioMed by Sysmex Corporation
  • Laboratory Corporation of America Holdings
  • Novo Nordisk A/S
  • Precision BioLogic
  • rHEALTH
  • Siemens AG
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bleeding Disorders Testing Market: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Bleeding Disorders Testing Market: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 260 Pages
  • Global
From
Bleeding Disorder Testing Market Report 2025 - Product Image

Bleeding Disorder Testing Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Bleeding Disorders Treatment - Global Strategic Business Report - Product Image

Bleeding Disorders Treatment - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Bleeding Disorders Treatment Market Report 2025 - Product Image

Bleeding Disorders Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hematology Analyzers and Reagents Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F - Product Image

Hematology Analyzers and Reagents Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.